Home Cart Sign in  
Chemical Structure| 635323-95-4 Chemical Structure| 635323-95-4

Structure of F-15599
CAS No.: 635323-95-4

Chemical Structure| 635323-95-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

F-15599 is a highly selective G-protein biased 5-HT1A receptor agonist with Ki value of 3.4nM.

Synonyms: NLX-101

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of F-15599

CAS No. :635323-95-4
Formula : C19H21ClF2N4O
M.W : 394.85
SMILES Code : ClC1=C(F)C=CC(C(N2CCC(F)(CNCC3=NC=C(C)C=N3)CC2)=O)=C1
Synonyms :
NLX-101
MDL No. :MFCD28502284
InChI Key :WAAXKNFGOFTGLP-UHFFFAOYSA-N
Pubchem ID :11741361

Safety of F-15599

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of F-15599

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Unpredictable chronic mild stress (UCMS) model Oral 8 mg/kg Single administration To evaluate the antidepressant-like effects of F15599 in the UCMS model. Results showed that a single administration of F15599 significantly reversed depressive-like behaviors in the FST and rescued deficits in p-ERK1/2 levels in the cortex and hippocampus of UCMS mice. Psychopharmacology (Berl). 2021 Aug;238(8):2249-2260
Male WTG rats Resident-intruder aggression model Intraperitoneal injection 0.0625, 0.125, 0.25, 0.5 and 1.0 mg/kg Single administration, behavioral test conducted 30 minutes after administration To evaluate the anti-aggressive effects of F15599. Results showed that F15599 significantly delayed attack latency and reduced aggressive behavior in a dose-dependent manner (ID50=0.095 mg/kg). At higher doses, it was accompanied by motor inactivity and reduced social engagement. Psychopharmacology (Berl). 2016 Mar;233(6):937-47
Wistar and Wistar-Kyoto rats Chronic mild stress (CMS) model of depression Intraperitoneal injection 0.04 or 0.16 mg/kg (NLX-101 and NLX-204), 10 mg/kg (ketamine) Twice daily (NLX-101 and NLX-204), once daily (ketamine), for 17 days To evaluate the effects of NLX-101, NLX-204, and ketamine in the CMS model on sucrose consumption (anhedonia measure), novel object recognition (NOR; working memory measure), and elevated plus maze (EPM; anxiety measure). Results showed that NLX-204 and NLX-101 (0.08–0.16 mg/kg i.p.), like ketamine (10 mg/kg i.p.), dose-dependently reversed CMS-induced sucrose intake deficit from treatment Day 1 in Wistar rats, with nearly full reversal observed at the higher dose on Days 8 and 15. These effects persisted for 3 weeks following treatment cessation. In the NOR test, both doses of NLX-101/NLX-204 and ketamine rescued the deficit in discrimination index caused by CMS on Days 3 and 17; all three compounds increased time spent in open arms (EPM), but only NLX-204 achieved statistical significance on Days 2 and 16. In Wistar-Kyoto rats, all three compounds were also active in the sucrose test and, to a lesser extent, in the NOR and EPM. In non-stressed rats (both strains), the three compounds produced no significant effects in all tests. Psychopharmacology (Berl). 2023 Nov;240(11):2419-2433
Sprague-Dawley rats Drug discrimination model Intraperitoneal injection 0.5 mg/kg 20 minutes pre-treatment Evaluate the effects of F-15599 in a drug discrimination model, showing that F-15599 fully substituted for the 8-OH-DPAT discriminative cue at 0.5 mg/kg Behav Pharmacol. 2021 Dec 1;32(8):652-659
Male Albino Swiss mice MK-801-induced cognitive impairment model Intraperitoneal injection 0.1 mg/kg Acute administration (single dose) or chronic administration (7 consecutive days) F15599 reversed MK-801-induced cognitive deficits in the NOR test and was effective in the Y-maze only at the highest dose. Chronic administration of F15599 with muscarinic receptor ligands reversed MK-801-induced deficits in the NOR test. Int J Mol Sci. 2021 Aug 10;22(16):8612
Rats T8 contusive SCI model Intraperitoneal injection 0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg Twice daily for 6 weeks To evaluate the effects of long-term NLX-112 treatment on locomotor function, LUT function, bladder morphology, and spinal 5-HT1A receptor expression after T8 contusive SCI. Results showed that NLX-112 significantly improved locomotion (dose-dependent), LUT function (reduced detrusor overactivity and improved EUS activity), bladder morphology (reduced bladder weight and wall thickness), and reduced SCI-upregulated spinal 5-HT1A receptors. Int J Mol Sci. 2024 Dec 30;26(1):239

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.66mL

2.53mL

1.27mL

25.33mL

5.07mL

2.53mL

References

 

Historical Records

Categories